AbbVie

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech reportify.cn. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits) timesunion.com reportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1st ts2.tech. Several catalysts have fueled this rally. In mid-September, AbbVie announced a patent settlement securing no U.S. generics

31 October 2025

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on record directorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8 (reached on Oct. 1) ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its

23 October 2025

Investment · Market Analysis · NYSE:ABBV · Pharmaceuticals · Stocks · Wall Street

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied (+5% in Europe) after Pfizer announced a U.S. drug-pricing deal reuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals (50-day MA ≈ $214; 200-day

11 October 2025

Biotech · Financial Analysis · Investing · NYSE:ABBV · Pharmaceuticals · Stock Market